BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 24676136)

  • 1. Molecular mechanisms of pulmonary arterial remodeling.
    Crosswhite P; Sun Z
    Mol Med; 2014 Apr; 20(1):191-201. PubMed ID: 24676136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of JAK2 protects mice against hypoxia-induced pulmonary arterial hypertension by repressing pulmonary arterial smooth muscle cell proliferation.
    Zhang L; Wang Y; Wu G; Rao L; Wei Y; Yue H; Yuan T; Yang P; Xiong F; Zhang S; Zhou Q; Chen Z; Li J; Mo BW; Zhang H; Xiong W; Wang CY
    Cell Prolif; 2020 Feb; 53(2):e12742. PubMed ID: 31943454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia- or PDGF-BB-dependent paxillin tyrosine phosphorylation in pulmonary hypertension is reversed by HIF-1α depletion or imatinib treatment.
    Veith C; Zakrzewicz D; Dahal BK; Bálint Z; Murmann K; Wygrecka M; Seeger W; Schermuly RT; Weissmann N; Kwapiszewska G
    Thromb Haemost; 2014 Dec; 112(6):1288-303. PubMed ID: 25231004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Smad-dependent and smad-independent induction of id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo.
    Yang J; Li X; Al-Lamki RS; Southwood M; Zhao J; Lever AM; Grimminger F; Schermuly RT; Morrell NW
    Circ Res; 2010 Jul; 107(2):252-62. PubMed ID: 20522807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sildenafil potentiates bone morphogenetic protein signaling in pulmonary arterial smooth muscle cells and in experimental pulmonary hypertension.
    Yang J; Li X; Al-Lamki RS; Wu C; Weiss A; Berk J; Schermuly RT; Morrell NW
    Arterioscler Thromb Vasc Biol; 2013 Jan; 33(1):34-42. PubMed ID: 23139294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of the bone morphogenetic protein system in endothelin- and aldosterone-induced cell proliferation of pulmonary arterial smooth muscle cells isolated from human patients with pulmonary arterial hypertension.
    Yamanaka R; Otsuka F; Nakamura K; Yamashita M; Otani H; Takeda M; Matsumoto Y; Kusano KF; Ito H; Makino H
    Hypertens Res; 2010 May; 33(5):435-45. PubMed ID: 20186146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical role for the advanced glycation end-products receptor in pulmonary arterial hypertension etiology.
    Meloche J; Courchesne A; Barrier M; Carter S; Bisserier M; Paulin R; Lauzon-Joset JF; Breuils-Bonnet S; Tremblay É; Biardel S; Racine C; Courture C; Bonnet P; Majka SM; Deshaies Y; Picard F; Provencher S; Bonnet S
    J Am Heart Assoc; 2013 Jan; 2(1):e005157. PubMed ID: 23525442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-221-3p promotes pulmonary artery smooth muscle cells proliferation by targeting AXIN2 during pulmonary arterial hypertension.
    Nie X; Chen Y; Tan J; Dai Y; Mao W; Qin G; Ye S; Sun J; Yang Z; Chen J
    Vascul Pharmacol; 2019 May; 116():24-35. PubMed ID: 28694128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Krüppel-like factor 5 contributes to pulmonary artery smooth muscle proliferation and resistance to apoptosis in human pulmonary arterial hypertension.
    Courboulin A; Tremblay VL; Barrier M; Meloche J; Jacob MH; Chapolard M; Bisserier M; Paulin R; Lambert C; Provencher S; Bonnet S
    Respir Res; 2011 Sep; 12(1):128. PubMed ID: 21951574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced Ca(2+)-sensing receptor function in idiopathic pulmonary arterial hypertension.
    Yamamura A; Guo Q; Yamamura H; Zimnicka AM; Pohl NM; Smith KA; Fernandez RA; Zeifman A; Makino A; Dong H; Yuan JX
    Circ Res; 2012 Aug; 111(4):469-81. PubMed ID: 22730443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldehyde dehydrogenase 2 protects against oxidative stress associated with pulmonary arterial hypertension.
    Xu T; Liu S; Ma T; Jia Z; Zhang Z; Wang A
    Redox Biol; 2017 Apr; 11():286-296. PubMed ID: 28030785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathophysiological roles of nuclear factor kappaB (NF-kB) in pulmonary arterial hypertension: effects of synthetic selective NF-kB inhibitor IMD-0354.
    Hosokawa S; Haraguchi G; Sasaki A; Arai H; Muto S; Itai A; Doi S; Mizutani S; Isobe M
    Cardiovasc Res; 2013 Jul; 99(1):35-43. PubMed ID: 23631839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baicalin inhibits hypoxia-induced pulmonary artery smooth muscle cell proliferation via the AKT/HIF-1α/p27-associated pathway.
    Zhang L; Pu Z; Wang J; Zhang Z; Hu D; Wang J
    Int J Mol Sci; 2014 May; 15(5):8153-68. PubMed ID: 24821539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydrogen ameliorates pulmonary hypertension in rats by anti-inflammatory and antioxidant effects.
    Kishimoto Y; Kato T; Ito M; Azuma Y; Fukasawa Y; Ohno K; Kojima S
    J Thorac Cardiovasc Surg; 2015 Sep; 150(3):645-54.e3. PubMed ID: 26095621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAR-2 inhibition reverses experimental pulmonary hypertension.
    Kwapiszewska G; Markart P; Dahal BK; Kojonazarov B; Marsh LM; Schermuly RT; Taube C; Meinhardt A; Ghofrani HA; Steinhoff M; Seeger W; Preissner KT; Olschewski A; Weissmann N; Wygrecka M
    Circ Res; 2012 Apr; 110(9):1179-91. PubMed ID: 22461388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension.
    Paulin R; Meloche J; Jacob MH; Bisserier M; Courboulin A; Bonnet S
    Am J Physiol Heart Circ Physiol; 2011 Nov; 301(5):H1798-809. PubMed ID: 21890685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selenoprotein P Promotes the Development of Pulmonary Arterial Hypertension: Possible Novel Therapeutic Target.
    Kikuchi N; Satoh K; Kurosawa R; Yaoita N; Elias-Al-Mamun M; Siddique MAH; Omura J; Satoh T; Nogi M; Sunamura S; Miyata S; Saito Y; Hoshikawa Y; Okada Y; Shimokawa H
    Circulation; 2018 Aug; 138(6):600-623. PubMed ID: 29636330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resveratrol prevented experimental pulmonary vascular remodeling via miR-638 regulating NR4A3/cyclin D1 pathway.
    Liu YY; Zhang WY; Wang CG; Huang JA; Jiang JH; Zeng DX
    Microvasc Res; 2020 Jul; 130():103988. PubMed ID: 32057731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension.
    Preston IR; Sagliani KD; Warburton RR; Hill NS; Fanburg BL; Jaffe IZ
    Am J Physiol Lung Cell Mol Physiol; 2013 May; 304(10):L678-88. PubMed ID: 23457185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P21-dependent protective effects of a carbon monoxide-releasing molecule-3 in pulmonary hypertension.
    Abid S; Houssaïni A; Mouraret N; Marcos E; Amsellem V; Wan F; Dubois-Randé JL; Derumeaux G; Boczkowski J; Motterlini R; Adnot S
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):304-12. PubMed ID: 24334871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.